TY - JOUR
T1 - Smoking cessation and risk of recurrent cardiovascular events and mortality after a first manifestation of arterial disease
AU - van den Berg, M. Johannek E.
AU - van der Graaf, Yolanda
AU - Deckers, Jaap W.
AU - de Kanter, Wanda
AU - Algra, Ale
AU - Kappelle, L. Jaap
AU - de Borst, Gert J.
AU - Cramer, Maarten-Jan M.
AU - Visseren, Frank L. J.
AU - Grobbee, D. E.
AU - Rutten, G. E. H. M.
AU - Leiner, T.
AU - Nathoe, H. M.
N1 - Funding Information:
For the SMART study, we gratefully acknowledge the contribution of the SMART research nurses, R. van Petersen (data manager)B.G.F. van Dinther (manager Utrecht Cardiovascular Cohort)and the members of the SMART study group: A. Algra, MD, PhD; Y. van der Graaf, MD, PhD; D. E. Grobbee, MD, PhD; G. E. H. M. Rutten, MD, PhD, Julius Center for Health Sciences and Primary Care; F. L. J. Visseren, MD, PhD, Department of Internal Medicine; G.J. de Borst, MD, PhD, Department of Vascular Surgery; L. J. Kappelle, MD, PhD, Department of Neurology; T. Leiner, MD, PhD, Department of Radiology; H.M. Nathoe, MD, PhD, Department of Cardiology. No funding was received for the present study. MJB, FLJV and YG designed the study. MJB performed the statistical data analysis and drafted the paper. All authors discussed and contributed to the theoretical framework, interpretation of the results, and revised and gave final approval of this manuscript.
Publisher Copyright:
© 2019 The Authors
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Aims: To quantify the relation between smoking cessation after a first cardiovascular (CV)event and risk of recurrent CV events and mortality. Methods: Data were available from 4,673 patients aged 61 ± 8.7 years, with a recent (≤1 year)first manifestation of arterial disease participating in the SMART-cohort. Cox models were used to quantify the relation between smoking status and risk of recurrent major atherosclerotic cardiovascular events (MACE including stroke, MI and vascular mortality)and mortality. In addition, survival according to smoking status was plotted, taking competing risk of non-vascular mortality into account. Results: A third of the smokers stopped after their first CV event. During a median of 7.4 (3.7–10.8)years of follow-up, 794 patients died and 692 MACE occurred. Compared to patients who continued to smoke, patients who quit had a lower risk of recurrent MACE (adjusted HR 0.66, 95% CI 0.49–0.88)and all-cause mortality (adjusted HR 0.63, 95% CI 0.48–0.82). Patients who reported smoking cessation on average lived 5 life years longer and recurrent MACE occurred 10 years later. In patients with a first CV event >70 years, cessation of smoking had improved survival which on average was comparable to former or never smokers. Conclusions: Irrespective of age at first CV event, cessation of smoking after a first CV event is related to a substantial lower risk of recurrent vascular events and all-cause mortality. Since smoking cessation is more effective in reducing CV risk than any pharmaceutical treatment of major risk factors, it should be a key objective for patients with vascular disease.
AB - Aims: To quantify the relation between smoking cessation after a first cardiovascular (CV)event and risk of recurrent CV events and mortality. Methods: Data were available from 4,673 patients aged 61 ± 8.7 years, with a recent (≤1 year)first manifestation of arterial disease participating in the SMART-cohort. Cox models were used to quantify the relation between smoking status and risk of recurrent major atherosclerotic cardiovascular events (MACE including stroke, MI and vascular mortality)and mortality. In addition, survival according to smoking status was plotted, taking competing risk of non-vascular mortality into account. Results: A third of the smokers stopped after their first CV event. During a median of 7.4 (3.7–10.8)years of follow-up, 794 patients died and 692 MACE occurred. Compared to patients who continued to smoke, patients who quit had a lower risk of recurrent MACE (adjusted HR 0.66, 95% CI 0.49–0.88)and all-cause mortality (adjusted HR 0.63, 95% CI 0.48–0.82). Patients who reported smoking cessation on average lived 5 life years longer and recurrent MACE occurred 10 years later. In patients with a first CV event >70 years, cessation of smoking had improved survival which on average was comparable to former or never smokers. Conclusions: Irrespective of age at first CV event, cessation of smoking after a first CV event is related to a substantial lower risk of recurrent vascular events and all-cause mortality. Since smoking cessation is more effective in reducing CV risk than any pharmaceutical treatment of major risk factors, it should be a key objective for patients with vascular disease.
UR - http://www.scopus.com/inward/record.url?scp=85066089174&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2019.03.019
DO - 10.1016/j.ahj.2019.03.019
M3 - Article
C2 - 31132583
SN - 0002-8703
VL - 213
SP - 112
EP - 122
JO - American Heart Journal
JF - American Heart Journal
ER -